<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Voxelotor: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Voxelotor: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Voxelotor: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="126260" href="/d/html/126260.html" rel="external">see "Voxelotor: Drug information"</a> and <a class="drug drug_patient" data-topicid="126406" href="/d/html/126406.html" rel="external">see "Voxelotor: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53890567"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Oxbryta</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F53894488"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Hemoglobin S (HbS) Polymerization Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F53894588"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a770d65-c27a-4082-a6b5-04827ca0d56f">Sickle cell disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sickle cell disease, treatment: Note:</b> May be given with or without hydroxyurea. Available as tablets or tablets for oral suspension; use caution during product selection based on patient's ability to swallow tablets whole.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to &lt;12 years:</p>
<p style="text-indent:-2em;margin-left:6em;">10 to &lt;20 kg: Oral: 600 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">20 to &lt;40 kg: Oral: 900 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥40 kg: Oral: 1,500 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 1,500 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F53894605"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to severe renal impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant pharmacokinetic differences were observed in pharmacokinetic studies in patients with CrCl of 15 to 89 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease requiring hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F53894608"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children 4 to &lt;12 years:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment needed.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child Pugh class C):</p>
<p style="text-indent:-2em;margin-left:6em;">10 to &lt;20 kg: Oral: Reduce dose to 300 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">20 to &lt;40 kg: Oral: Reduce dose to 600 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥40 kg: Depends upon dosage form used:</p>
<p style="text-indent:-2em;margin-left:8em;">Tablets: Oral: Reduce dose to 1,000 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Tablets for oral suspension: Oral: Reduce dose to 900 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment needed.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child Pugh class C): Tablets: Oral: Reduce dose to 1,000 mg once daily.</p></div>
<div class="block doa drugH1Div" id="F53917154"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="126260" href="/d/html/126260.html" rel="external">see "Voxelotor: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b6a9e50-ed98-4ee4-8a59-1ac97382a77d">Sickle cell disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sickle cell disease: Oral:</b> 1.5 g once daily; may be administered with or without hydroxyurea (Vichinsky 2019).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i>If a dose is missed, continue dosing on the day following the missed dose.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F53917156"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl 15 to 89 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling; however, no clinically significant differences in pharmacokinetics were observed in patients with mild to severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease requiring dialysis: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F53917157"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild (Child Pugh class A) or moderate (Child Pugh class B) impairment: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe (Child Pugh class C) impairment: Reduce voxelotor dose to 1 g once daily.</p></div>
<div class="block adr drugH1Div" id="F53899932"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adolescents and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (23%), diarrhea (23%), nausea (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (32%; severe headache: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Pulmonary embolism (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (&lt;10%; severe hypersensitivity reaction: 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, drug reaction with eosinophilia and systemic symptoms</p></div>
<div class="block coi drugH1Div" id="F53880521"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Serious hypersensitivity (eg, generalized rash, urticaria, mild shortness of breath, mild facial swelling, eosinophilia) to voxelotor or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F53917138"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious hypersensitivity reactions have occurred rarely, and may include generalized rash, urticaria, mild dyspnea, mild facial swelling, and eosinophilia. Drug reaction with eosinophilia and systemic symptoms (DRESS) has also occurred. Discontinue voxelotor if a hypersensitivity reaction, including DRESS, occurs and manage as clinically necessary. Do not reinitiate voxelotor in patients who developed a hypersensitivity reaction with prior voxelotor exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Severe hepatic impairment increases voxelotor exposure. Reduce dose in patients with severe (Child Pugh class C) impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Laboratory test interference: Voxelotor may interfere with high-performance liquid chromatography measurement of Hb subtypes (HbA, HbS, and HbF). Chromatography should be performed when voxelotor has not been administered in the immediate 10 days prior if precise Hb species quantitation is required.</p></div>
<div class="block foc drugH1Div" id="F53890568"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxbryta: 300 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Soluble, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxbryta: 300 mg</p></div>
<div class="block geq drugH1Div" id="F53890566"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53986099"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet,Dispersible</b> (Oxbryta Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $242.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Oxbryta Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $242.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $161.52</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F53894611"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to food.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Swallow tablet whole; do not cut, crush, or chew tablet.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet for oral suspension: Dose can be dispersed in room temperature clear drink; the minimum volume of liquid required to disperse tablet(s) varies with dose (see table). Place dose in cup with appropriate volume of <b>clear</b> drink (water, soda, apple juice, electrolyte drinks, flavored drinks, or sports drinks). Once tablets start to dissolve, swirl cup until contents fully dispersed; wait 1 to 5 minutes and then swirl contents in cup again; tablet(s) will not completely dissolve and there may be small clumps in the mixture. Administer orally. Resuspend any residue remaining in cup with more clear drink and administer, to ensure full dose received; repeat until no residue left in dosing cup. Do not swallow whole, cut, crush, or chew tablets for oral suspension.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Volume (mL) to Disperse Tablets</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Daily Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of 300 mg Tablets for Oral Suspension</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>MINIMUM Volume of Clear Drink</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mL</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mL</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">900 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 mL</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 mL</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,500 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">25 mL</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,100 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">35 mL</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 mL</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed or incomplete dose: </i>If dose missed or not entirely consumed, resume dosing the following day.</p></div>
<div class="block adm drugH1Div" id="F53917159"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer orally with or without food.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Swallow tablets whole; do not cut, crush, or chew the tablets.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets for oral solution: May be used in patients unable to swallow tablets; do not swallow whole, cut, crush, or chew the tablets. Disperse the number of tablets needed to achieve the recommended dose in a cup with room temperature clear liquid (eg, water, clear soda, apple juice, clear electrolyte drinks, clear flavored drinks, clear sports drinks). Use at least 5 mL of liquid per each 300 mg tablet. Swirl contents of cup for 1 to 5 minutes as tablets start to disintegrate until fully dispersed. Swirl contents again prior to administration; small tablet clumps will still be visible in the mixture. Resuspend any residue left in the cup with more clear liquid and drink; repeat until all residue is administered.</p></div>
<div class="block sts drugH1Div" id="F53917141"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 30°C (68°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53894496"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Treatment of sickle cell disease (FDA approved in ages ≥4 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Indication based on accelerated approval due to improved hemoglobin in initial trials; continued approval may be contingent upon confirmatory trials.</p></div>
<div class="block mst drugH1Div" id="F53917134"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Voxelotor may be confused with venetoclax, vorinostat.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F53894504"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor), UGT1A1, UGT1A9; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F53894501"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Voxelotor. Management: Avoid concomitant use of voxelotor and moderate CYP3A4 inducers. If unavoidable, increase the voxelotor dose to 2,000 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Voxelotor. Management: Avoid concomitant use of voxelotor and strong CYP3A4 inducers. If  unavoidable, increase the voxelotor dose to 2,500 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exagamglogene Autotemcel: Voxelotor may diminish the therapeutic effect of Exagamglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Voxelotor may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F53917136"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Sickle cell disease increases the risk of adverse maternal and fetal outcomes, including an increased risk for vaso-occlusive crises, preeclampsia, eclampsia, intrauterine growth restriction, preterm delivery, low birth weight, and maternal and perinatal mortality.</p></div>
<div class="block mopp drugH1Div" id="F53894612"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hemoglobin, hepatic function. Monitor for hypersensitivity reactions (eg, rash, urticaria, mild shortness of breath, mild facial swelling, eosinophilia).</p></div>
<div class="block pha drugH1Div" id="F53917142"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Voxelotor is an HbS polymerization inhibitor that reversibly binds to Hb and stabilizes the oxygenated Hb state. Through the increased Hb affinity for oxygen, voxelotor demonstrates dose-dependent inhibition of HbS polymerization, and may inhibit RBC sickling, improve RBC deformability, and reduce whole blood viscosity. Voxelotor may also extend RBC half-life and reduce anemia and hemolysis (Vichinsky 2019).</p></div>
<div class="block phk drugH1Div" id="F53894497"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Exposures in children ≥4 years and adolescents are similar to in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: A high-fat, high-calorie meal increased voxelotor whole blood AUC and C<sub>max</sub> by 42% and 45%, respectively (compared to a fasted state); likewise, plasma AUC and C<sub>max</sub> increased by 42% and 95%, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Central compartment: 333 L; Peripheral compartment: 72.3 L; distributed predominantly into RBCs.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99.8%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic through phase I metabolism (oxidation and reduction), phase II metabolism (glucuronidation), and combinations of phase I and II metabolism. Oxidation is mediated by CYP3A4, CYP3A5, CYP2C19, CYP2B6, CYP2C9, UGT1A1, and UGT1A9.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 38.7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Median: 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: ~63% (33% as unchanged drug); Urine: ~36% (0.08% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 6.1 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F53917150"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Following a single 900 mg dose, whole blood exposures in subjects with severe renal impairment (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>) were 25% lower compared to subjects with normal renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Voxelotor AUC in whole blood were 14%, 15%, and 90% higher in subjects with mild (Child Pugh class A), moderate (Child Pugh class B), and severe (Child Pugh class C) impairment, respectively, as compared to subjects with normal hepatic function.</p>
<p style="text-indent:-2em;margin-left:2em;">HbSC genotype: Voxelotor steady-state whole blood AUC and C<sub>max</sub> were 50% and 45% higher, respectively, in patients with the HbSC genotype compared to patients with the HbSS genotype; plasma AUC and C<sub>max</sub> were 23% and 15% higher, respectively, in patients with the HbSC genotype compared to patients with the HbSS genotype.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58215922"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Oxbryta</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Oxbryta</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Oxbryta</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Oxbryta</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Oxbryta</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-GBT.1">
<a name="GBT.1"></a>Oxbryta (voxelotor) [prescribing information]. South San Francisco, CA: Global Blood Therapeutics Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31199090">
<a name="31199090"></a>Vichinsky E, Hoppe CC, Ataga KI, et al; HOPE Trial Investigators. A phase 3 randomized trial of voxelotor in sickle cell disease. <i>N Engl Med.</i> 2019;381(6):509-519. doi: 10.1056/NEJMoa1903212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/voxelotor-pediatric-drug-information/abstract-text/31199090/pubmed" id="31199090" target="_blank">31199090</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 126391 Version 71.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
